ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

Rhea-AI Summary

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company specializing in immunology, has announced its upcoming second quarter 2024 financial results and corporate update. The company will host a conference call on Tuesday, August 13, 2024, at 5:00 p.m. ET to discuss these matters. Investors and interested parties can access a live webcast of the conference call through the company's website under the Events & Presentations section. For those unable to attend the live event, a replay of the webcast will be available on ACELYRIN's website for 90 days following the call, providing ample opportunity for stakeholders to review the information presented.

Positive

• ACELYRIN is a late-stage clinical biopharma company, indicating advanced progress in drug development
• The company is publicly traded on Nasdaq, providing liquidity for investors
• ACELYRIN is offering transparency by hosting a public conference call for financial results and corporate updates

Negative

• None.

LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, August 13, 2024 at 5:00 p.m. ET to discuss its second quarter 2024 financial results and provide a corporate update.

A live webcast of the conference call will be available on the Company’s website under Events & Presentations. A replay of the webcast will be available on the Company’s website for 90 days.

About ACELYRIN, INC.
ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN has two programs in late-stage clinical development. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R advancing into Phase 2b/3 development for the treatment of thyroid eye disease. Izokibep is a next generation inhibitor of IL-17A in Phase 2b/3 development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis.

For more information about ACELYRIN, visit us at www.acelyrin.com or follow us on LinkedIn and X.

Forward Looking Statements
Some statements in this press release are, or may be considered, forward-looking statements, including statements regarding ACELYRIN’s progress, business plans and clinical trials, as well as the potential future benefits of our product candidates. While ACELYRIN, INC. considers any projections to be based on reasonable assumptions, these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated in such forward-looking statements.

ACELYRIN Contacts:
Tyler Marciniak
Vice President of Investor Relations
and Corporate Affairs
investors@acelyrin.com
media@acelyrin.com

FAQ

When will ACELYRIN, INC. (SLRN) report its Q2 2024 financial results?

ACELYRIN, INC. (SLRN) will report its second quarter 2024 financial results on Tuesday, August 13, 2024, during a conference call at 5:00 p.m. ET.

How can investors access ACELYRIN's (SLRN) Q2 2024 earnings call?

Investors can access ACELYRIN's (SLRN) Q2 2024 earnings call via a live webcast available on the company's website under the Events & Presentations section.

For how long will the replay of ACELYRIN's (SLRN) Q2 2024 earnings call be available?

The replay of ACELYRIN's (SLRN) Q2 2024 earnings call will be available on the company's website for 90 days following the live event.

What is ACELYRIN's (SLRN) primary focus as a biopharma company?

ACELYRIN (SLRN) is a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology.